Results 171 to 180 of about 1,443,667 (357)

Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Fanastomig (also known as EMB‐02) is a bispecific antibody targeting programmed cell death protein‐1(PD‐1) and lymphocyte activation gene‐3 (LAG‐3), developed for the treatment of advanced solid tumors. A first‐in‐human (FIH) Phase I study (NCT04618393) evaluated safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD ...
Chengjun Jiang, Fang Ren, Mingfei Zhang, Qiaoyang Lu, Shuqi Zeng, Guang Yang, Yonghong Zhu   +6 more
wiley   +1 more source

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

Cell Insight
As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing antibodies and emergence of immune escape, the role of bispecific antibodies becomes crucial in bolstering antiviral activity and suppressing immune evasion.
Zhaohui Li, Zengyuan Zhang, Steven T. Rosen, Mingye Feng   +3 more
doaj  

Leveraging Large Language Models to Predict Antibody Biological Activity Against Influenza A Hemagglutinin [PDF]

arXiv
Monoclonal antibodies (mAbs) represent one of the most prevalent FDA-approved modalities for treating autoimmune diseases, infectious diseases, and cancers. However, discovery and development of therapeutic antibodies remains a time-consuming and expensive process. Recent advancements in machine learning (ML) and artificial intelligence (AI) have shown
arxiv  

A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT The administration of biologics can lead to immunogenic responses that trigger anti‐drug antibody (ADA) formation. ADAs can decrease drug exposure. A population pharmacokinetic (popPK) model was developed to describe clinical PK data with and without ADA‐driven exposure loss with CEA‐directed T‐cell bispecific antibody cibisatamab.
Javier Sanchez, Philippe B. Pierrillas, Nicolas Frey, Gregor P. Lotz, Siv Jönsson, Lena E. Friberg, Nicolas Frances   +6 more
wiley   +1 more source

Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences [PDF]

arXiv
To build effective therapeutics, biologists iteratively mutate antibody sequences to improve binding and stability. Proposed mutations can be informed by previous measurements or by learning from large antibody databases to predict only typical antibodies.
arxiv  

Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2

, 1994
B. J. Kroesen, Jan Buter, D.Th. Sleijfer, René A. J. Janssen, Wta van der Graaf, TH The, L de Leij, NH Mulder   +7 more
openalex   +2 more sources

Anti-CD3/Anti-Epidermal Growth Factor Receptor-Bispecific Antibody Retargeting of Lymphocytes against Human Neoplastic Keratinocytes in an Autologous Organotypic Culture Model [PDF]

, 2002
Isabelle Renard, Delia Mezzanzanica, Silvana Canevari, Silvano Ferrini, Jacques Boniver, Philippe Delvenne, Nathalie Jacobs   +6 more
openalex   +1 more source

Development of a Heuristic Machine Analogy Method for Model Simplification With an Application to a Large‐Scale Model of Gi/Gs Signaling

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Model simplification is a process to simplify large‐scale mathematical models to enable easy applications such as simulation and parameter estimation. A novel heuristic machine analogy method of model simplification was developed and applied to a motivating example of a model for cAMP signaling switch induced by Gi/Gs pathway competition for ...
Liang Yang, David Finlay, Michelle Glass, Stephen Duffull   +3 more
wiley   +1 more source

An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies

Antibodies
Bispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong, I-Ling Chen, Lance Larrabee, Manali S. Sawant, Germaine Fuh, Patrick Koenig   +5 more
doaj   +1 more source

Relation-Aware Equivariant Graph Networks for Epitope-Unknown Antibody Design and Specificity Optimization [PDF]

arXiv
Antibodies are Y-shaped proteins that protect the host by binding to specific antigens, and their binding is mainly determined by the Complementary Determining Regions (CDRs) in the antibody. Despite the great progress made in CDR design, existing computational methods still encounter several challenges: 1) poor capability of modeling complex CDRs with
arxiv